While the United States undertakes unprecedented adjustments to its vaccine schedules, a particular individual appears somewhat surprisingly: Høeg, an American of Danish descent physician and public health researcher who initially gained attention by expressing skepticism about Covid vaccinations throughout the global health crisis and has concentrated on potential fatalities following Covid vaccination in her brief tenure at the US Food and Drug Administration (FDA).
Proposed Shifts to Childhood Vaccine Schedule
Health officials had intended to reveal sweeping changes to the pediatric vaccination calendar recently, synchronizing the US with the Danish vaccine program, it is understood – a major change that would place the US at odds with much of the international standard with little proof for improved outcomes. This reveal has been delayed until the next year.
In place of the top vaccines chief, Dr. Høeg is scheduled to address the audience at the gathering. She was recently named acting director of the FDA’s drug evaluation center, the fifth person to head the center this calendar year.
A Shift at the FDA
Høeg's temporary position might represent a strengthened alliance between the drug and vaccine centers as Dr. Høeg and Dr. Prasad solidify control at the FDA – and it points to a renewed priority upon reevaluating already-approved vaccines at the FDA.
Høeg has frequently advocated for discontinuing specific pediatric immunization guidelines in the US in order to be more like Denmark's approach, a nation with nationalized medicine and a citizenry about the population of the state of Wisconsin.
So far comments, she has persisted in emphasizing on vaccination policy – usually the responsibility of Dr. Prasad, director of the FDA’s vaccine center – rather than drug regulation.
Doubts Over Expertise
Høeg has little discernible background in medication creation, regulation or administrative roles, which has been standard for former heads of the biologics center. She has worked at the FDA as a key advisor to the agency head and CBER since spring.
“She doesn’t seem to have the necessary background” for leading the pharmaceutical oversight division, stated Dr. Jonathan Howard. “She has not conducted a randomized controlled trial. She lacks experience in managing a major agency. She is not an expert in drug approvals.”
Previous commissioners of the center would “grasp laws and regulations and the underlying principles of pharmaceutical innovation”, commented Dr. Janet Woodcock. “Clearly, she lacks the sort of resume that prior appointees who headed the center have had.”
This division has an immense range of responsibilities at the agency, she emphasized.
“The public just focuses on the novel medication approvals, but the off-patent medication office clears a multitude of off-brand pharmaceuticals. There is also a biologic copycat branch, OTC medication office and other areas, and every single one must be supervised,” Dr. Woodcock said. “The area you neglect, that is the part that I always told people is going to bite you.”
Additionally, a substantial management element to the job, which supervises in excess of 5,000 staff members. “It’s a huge leadership role, if you execute it properly,” she added.
Response and Controversial Policies
When asked about questions about Høeg’s credentials and whether this assignment represents increased cooperation among agency officials on vaccines, a representative said that the “concerns rely on inaccurate assumptions”.
“This background is consistent with the responsibilities of her position,” the representative stated, noting the period Dr. Høeg spent guiding the agency head on “drug safety and regulatory science, including computational safety modeling and immunization monitoring”.
In her interim role, Høeg inherits the commissioner’s recently launched fast-track approval initiative, a disputed one-day medication authorization process that apparently concerned her predecessors. “How are these therapies being picked for this fast-track system? Who makes the decisions?” Howard asked. “There is a lot of lack of transparency happening at the FDA right now.”
Overall, he stated, “the agency seems to be moving towards laxer oversight of most medications, aside from vaccines.”
Documented Track Record on Vaccines
Concerning vaccines, Dr. Høeg has a more documented, if problematic, track record, critics observe. She released a study using unverified crowd-sourced reports to assess the frequency of heart inflammation after COVID-19 vaccination. She advised the Florida chief medical officer Dr. Joseph Ladapo, who allegedly have altered data to indicate Covid vaccines are more dangerous than they are.
Among her “desired changes” for the current federal leadership encompassed changing rules for novel immunizations and halting “non-essential” immunizations, she stated after the election on a online show. At the FDA, Dr. Høeg has according to sources proposed excluding adolescent males from getting Covid vaccines.
“She is an all-around dogmatist who commences with her beliefs and tailors the evidence to accommodate the data in a highly misleading, dishonest fashion,” Howard stated.
Taking Control and a “Campaign of Retribution”
Dr. Høeg aligned with other skeptics, {like|